JPH07144026A - Cancer treating device by photoimmune treatment method - Google Patents
Cancer treating device by photoimmune treatment methodInfo
- Publication number
- JPH07144026A JPH07144026A JP6124802A JP12480294A JPH07144026A JP H07144026 A JPH07144026 A JP H07144026A JP 6124802 A JP6124802 A JP 6124802A JP 12480294 A JP12480294 A JP 12480294A JP H07144026 A JPH07144026 A JP H07144026A
- Authority
- JP
- Japan
- Prior art keywords
- light
- cancer
- section
- path
- optical fiber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、光免疫療法により癌治
療を行なうための装置に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a device for treating cancer by photoimmunotherapy.
【０００２】[0002]
【従来の技術】最近の癌治療は、早期発見・早期治療に
よりめざましい進歩を遂げてきた。しかし、発見の遅れ
た癌については、外科手術、放射線療法、化学療法など
を行なうものの、免疫力及び体力が著しく低下し、かえ
って癌の転移を助ける結果となり、大きな問題となって
いる。また温熱療法などの実用化も進んでいるが、高エ
ネルギーを用いるために正常細胞などへの障害は免れな
い。近年、光化学療法が注目され、その一つとしてフォ
トダイナミック療法（ＰＤＴ）が施術されている。この
療法は、ヘマトポルフィリンなどの色素を含む薬液を静
脈注射や経口投与し、癌部位を選択的に染色した後、癌
巣に高エネルギーのレーザー光を照射して癌細胞を破壊
する方法である。しかし、薬剤が癌部位に集積せず効果
が得られなかったり、また発生する活性酸素により癌巣
のみでなく、その周辺の正常細胞までも破壊されること
もあり、これも大きな問題となっている。2. Description of the Related Art Recent cancer treatments have made remarkable progress by early detection and treatment. However, although cancers that have been discovered lately are subjected to surgery, radiation therapy, chemotherapy, etc., their immunity and physical strength are significantly reduced, resulting in the help of cancer metastasis, which is a major problem. Although hyperthermia is being put to practical use, damage to normal cells is unavoidable due to the use of high energy. In recent years, photochemotherapy has attracted attention, and photodynamic therapy (PDT) has been performed as one of them. This therapy is a method of destroying cancer cells by irradiating a cancer site with high-energy laser light after selectively injecting a drug solution containing a dye such as hematoporphyrin intravenously or orally and selectively staining the cancer site. . However, the drug does not accumulate at the cancer site and no effect is obtained, and not only the cancer nest but also normal cells around it may be destroyed by the generated active oxygen, which is also a big problem. There is.
【０００３】[0003]
【発明が解決しようとする課題】癌は著しい増殖力があ
るので、これに立ち向かうためには生体防衛能力の増強
をはかり、それを最大限に発揮する治療法を開発するこ
とが強く望まれている。本発明者らはこの現状を考え、
種々検討を加えたところ、光免疫療法によって生体の防
衛能力の著しい増強が可能となることを見出した。光免
疫療法とは本研究者らが行なってきた研究から命名され
たもので、光増感剤を投与してさらに一定の光を照射す
ることにより、生体の免疫機能を増強する全く新しい癌
治療法である。この新しい治療法を体内のいたるところ
に生じる癌に、取扱いが簡単で、しかも正確に実施する
ことのできる適切な装置が必要となり、本発明者らは種
々検討した結果、新しい光免疫療法による癌治療装置を
発明するに至った。[Problems to be Solved by the Invention] Since cancer has a remarkable proliferative potential, in order to counter this, it is strongly desired to enhance the defense ability of the living body and develop a therapeutic method that maximizes it. There is. The present inventors have considered this situation,
Through various studies, it was found that photoimmunotherapy can significantly enhance the defense ability of the living body. Photoimmunotherapy was named after the research conducted by the present researchers.It is a completely new cancer treatment that enhances the immune function of the body by administering a photosensitizer and then irradiating it with a certain amount of light. Is the law. For this cancer that occurs everywhere in the body, an appropriate device that is easy to handle and that can be accurately performed is required. As a result of various studies by the present inventors, cancer by new photoimmunotherapy has been found. Invented a therapeutic device.
【０００４】[0004]
【課題を解決するための手段】本発明は光源部、光誘導
部及び光導入路と薬液流入路から構成される注入部を備
えた光免疫療法による癌治療装置に関するものである。
光源部にはレーザー発振装置、発光ダイオードやハロゲ
ン光などの発振装置が組み込まれて、発生した光は光誘
導部を通って、光導入路へ送られ、その先端部より癌巣
に直接照射することができる。注入部は光導入路と薬液
流入路から構成され、薬液流入路を形成する管の中に光
導入路を内蔵することができる構造となっている。光導
入路は薬液流入路を形成する管の中にその内径より小さ
い外径を有する誘導管を予め成形し、この中に光ファイ
バーを挿入して形成してもよく、又この誘導管を成形す
ることなく、直接光ファイバーを挿入して、この光ファ
イバーを光導入路となしてもよい。薬液は薬液注入器よ
り薬液流入路を通ってその先端部より注射により癌巣へ
直接注入される。この薬液注入器と注入部は使用にあた
っては順次新しいものに取り換えるディスポーザブルに
すると便利である。また胃癌のように内視鏡との併用が
より有効な治療効果をもたらすと予想される場合には、
内視鏡内部に注射針を装着すると便利であり、注射針や
コネクターの形状、寸法や位置を変えて適宜適応させる
ことができる。The present invention relates to a cancer treatment apparatus by photoimmunotherapy having a light source section, a light guide section, and an injection section composed of a light introduction path and a drug solution inflow path.
A laser oscillation device, an oscillation device such as a light emitting diode or a halogen light is incorporated in the light source part, and the generated light is sent to the light introduction path through the light guiding part and directly radiated to the cancerous nest from its tip. be able to. The injection part is composed of a light introduction path and a chemical solution inflow path, and has a structure in which the light introduction path can be built in a tube forming the chemical solution inflow path. The light introducing path may be formed by previously molding a guide tube having an outer diameter smaller than the inner diameter of the tube forming the chemical solution inflow path, and inserting an optical fiber into the guide tube. Alternatively, the optical fiber may be directly inserted and the optical fiber may be used as a light introduction path. The drug solution is directly injected from the drug solution injector through the drug solution inflow path to the cancerous lesion by injection from its tip. It is convenient to make the liquid medicine injector and the injector part disposable so that they can be sequentially replaced with new ones before use. In addition, when it is expected that the combined use with an endoscope will bring about a more effective therapeutic effect as in gastric cancer,
It is convenient to mount an injection needle inside the endoscope, and the shape, size and position of the injection needle and the connector can be changed to suit the situation.
【０００５】図を用いて本発明を更に詳細に説明する。
光源部１で発生した光は光ファイバーで形成される光誘
導部２を通って注入部３にある光導入路４へ導かれ、そ
の先端より癌巣へ照射される。光誘導部と光導入路はコ
ネクター９で接続されている。しかし、コネクターを設
けることなく、光誘導部と光導入路とは一体連続的な光
ファイバーで構成されてもよい。一方、薬液はコネクタ
ー８のコックを開き、薬液注入器７より薬液流入路６を
通って、その先端５より注射により癌巣へ直接注入され
る。コネクターとコックとは機能分離して別の箇所へ設
けてもよい。図２はディスポーザブルな注入部の一実施
態様を示す注射針の概略説明図である。光導入路４は光
ファイバーで形成され、薬液流入路６の管の中に装着さ
れている。この光ファイバーは使用時に注入部に装着し
てもよく、また注入部に予め装着した製品を購入、使用
することもできる。図３は注入部の他の実施態様を示す
留置針の概略説明図である。留置針（注入部）３の円筒
状の外管１０の中に針１１を装着した状態で生体内へ穿
刺した後に針をゴムシール１２の位置まで引き抜く。針
を完全に引き抜いた時は針導入口１３をキャップや栓で
完全にシールする。次に薬液注入器より圧送された薬液
が薬液流入口１４より注入され、薬液流入路６（針１１
が引き抜かれて生じた空洞）の先端より癌巣へ注射され
る。薬液流入口の内側にはテーパーを設けて薬液注入器
側のパイプと接続する。薬液注射後光ファイバー１５を
光ファイバー導入口１６より針１１を引き抜いて生じた
空洞６内へ誘導し、注入部の先端まで挿入し、光源部か
ら誘導された光を癌巣へ照射する。光照射が終わると留
置針の外管を体外へ抜き去る。留置針の外管は生体適合
性のよい材質で形成されており、穿刺時の衝撃を柔らげ
るとともに、長期間体内に留置することが可能である。
このような材質としてはポリエステル、アクリルやフッ
素樹脂などを挙げることができる。図４は留置針の他の
実施態様を示す概略説明図である。留置針３の外管１０
内に円弧状の針１１を装着し、この針の内面に光ファイ
バー１５を乗せて、留置針の先端まで光ファイバーを挿
入する。針の内面がガイドとなってスムーズに光ファイ
バーを装着することができる。穿刺後針のみを引き抜
き、残った光ファイバーをゴムシール１２で充分固定
し、薬液のリークや光ファイバーの動きを防ぐ。それか
ら薬液の注射と光照射を行ない、留置針全部を体外へ抜
き去る。図５は留置針の他の実施態様を示す概略説明図
である。留置針の外管１０の中に針１１と光ファイバー
１５が同時に独立に装着される構造となっている。穿刺
後針１１を引き抜き、針導入口１３を完全にシールし、
薬液のリークを防ぐ。光ファイバー１５は針導入口１３
とは別の箇所に設けられた光ファイバー導入口１６より
挿入されている。薬液は薬液流入口１４より注入され、
薬液流入路６を通ってその先端より癌巣へ注射される。The present invention will be described in more detail with reference to the drawings.
The light generated by the light source unit 1 is guided to the light introduction path 4 in the injection unit 3 through the light guiding unit 2 formed of an optical fiber, and is irradiated to the cancer nest from the tip thereof. The light guide section and the light introduction path are connected by a connector 9. However, without providing a connector, the light guiding portion and the light introducing path may be configured as an integrated continuous optical fiber. On the other hand, the drug solution is directly injected into the cancerous lesion by injection from the tip 5 of the drug solution injector 7 through the drug solution inflow path 6 by opening the cock of the connector 8. The connector and the cock may be functionally separated and provided at different locations. FIG. 2 is a schematic explanatory view of an injection needle showing an embodiment of the disposable injection part. The light introduction path 4 is formed of an optical fiber and is installed in the tube of the chemical solution inflow path 6. This optical fiber may be attached to the injection part at the time of use, or a product already attached to the injection part may be purchased and used. FIG. 3 is a schematic explanatory view of an indwelling needle showing another embodiment of the injection part. The needle 11 is inserted into the cylindrical outer tube 10 of the indwelling needle (injection part) 3 and punctured into the living body, and then the needle is pulled out to the position of the rubber seal 12. When the needle is completely withdrawn, the needle inlet 13 is completely sealed with a cap or stopper. Next, the drug solution pumped from the drug solution injector is injected from the drug solution inlet 14, and the drug solution inflow path 6 (needle 11
It is injected into the cancer nest through the tip of the hollow). A taper is provided on the inside of the drug solution inlet to connect with a pipe on the drug solution injector side. After injection of the drug solution, the optical fiber 15 is guided into the cavity 6 created by pulling out the needle 11 from the optical fiber introduction port 16 and inserted up to the tip of the injection part, and the light guided from the light source part is applied to the cancer nest. When the light irradiation is finished, the outer tube of the indwelling needle is pulled out of the body. The outer tube of the indwelling needle is formed of a material having a good biocompatibility, which can soften the impact at the time of puncture and can be left in the body for a long time.
Examples of such materials include polyester, acrylic and fluororesin. FIG. 4 is a schematic explanatory view showing another embodiment of the indwelling needle. Outer tube 10 of indwelling needle 3
An arc-shaped needle 11 is mounted inside, and an optical fiber 15 is placed on the inner surface of this needle to insert the optical fiber to the tip of the indwelling needle. The inner surface of the needle can be used as a guide to smoothly attach the optical fiber. After the puncture, only the needle is pulled out, and the remaining optical fiber is sufficiently fixed by the rubber seal 12 to prevent leakage of the chemical solution and movement of the optical fiber. Then, the drug solution is injected and light is irradiated, and all the indwelling needle is pulled out of the body. FIG. 5 is a schematic explanatory view showing another embodiment of the indwelling needle. The needle 11 and the optical fiber 15 are simultaneously and independently mounted in the outer tube 10 of the indwelling needle. After puncture, pull out the needle 11 to completely seal the needle introduction port 13,
Prevents leakage of chemicals. The optical fiber 15 is the needle inlet 13
It is inserted through an optical fiber introducing port 16 provided at a location different from the above. The chemical solution is injected from the chemical solution inlet 14,
It is injected into the cancerous lesion from the tip through the drug solution inflow path 6.
【０００６】本発明に用いられる薬液はシアニン色素を
有効成分とする。このシアニン色素は光照射によってマ
クロファージ（Ｍφ）の活性が著しく増強されるタイプ
の色素であればよく、その代表例は一般式（１）に示さ
れる色素である。The chemical solution used in the present invention contains a cyanine dye as an active ingredient. The cyanine dye may be any dye of the type in which the activity of macrophages (Mφ) is remarkably enhanced by light irradiation, and a typical example thereof is the dye represented by the general formula (1).
【化１】 ナフトチアゾール、キノリン、ベンゾオキサゾール、イ
ンドール、ナフトインドール などより選ばれる同一ま
たは異種の含窒素複素環核であり、これらの核は一つま
たは複数個の置換基を有してもよい。好適な置換基とし
ては、アルキル基、アルコキシ基、アルキルカルボニル
オキシ基、アルコキシカルボニル基、カルボキシ基、置
換基を有してもよいスルホンアミド基、アシルアミノ
基、アルキルアミノ基、ジアルキルアミノ基、アミノ
基、メチレンジオキシ基、クロルやヨードなどのハロゲ
ンが挙げられる。Ｒ１びＲ２はそれぞれ独立に置換基を
有してもよいアルキル基を表す。一つの含窒素複素環と
これに結合するアルキル基の炭素数の総和が８〜１４個
であるシアニン色素が細胞膜付着性などの点から特に有
効である。Ｘはクロル、ブロム、ヨード等のハロゲン、
ｐ−トルエンスルホン酸残基、過塩素酸残基、硼弗化水
素酸残基等のアニオンを表す。Ｚは−（ＣＨ＝ＣＨ）ｎ
−ＣＨ＝（ｎ＝０，１，２，３）（メソ位にアルキル基
またはハロゲンを有してもよい。）または−ＣＨ＝ＣＨ
−Ｃ（Ｙ）＝ＣＨ−ＣＨ＝を表す。ここでＹは、一般式
（２）で表される四級化された複素環核（記号は前記と
同じ意味を表す。）を示す。[Chemical 1] It is the same or different nitrogen-containing heterocyclic nucleus selected from naphthothiazole, quinoline, benzoxazole, indole, naphthindole and the like, and these nuclei may have one or more substituents. Suitable substituents are an alkyl group, an alkoxy group, an alkylcarbonyloxy group, an alkoxycarbonyl group, a carboxy group, a sulfonamide group which may have a substituent, an acylamino group, an alkylamino group, a dialkylamino group, an amino group. , A methylenedioxy group, and halogens such as chloro and iodo. R 1 and R 2 each independently represent an alkyl group which may have a substituent. A cyanine dye in which one nitrogen-containing heterocycle and the total number of carbon atoms of the alkyl groups bonded thereto are 8 to 14 is particularly effective from the viewpoint of cell membrane adhesion and the like. X is a halogen such as chlorine, bromine or iodine,
Represents anions such as p-toluenesulfonic acid residue, perchloric acid residue, and borofluoric acid residue. Z is-(CH = CH) n
-CH = (n = 0,1,2,3) (may have an alkyl group or halogen at meso position) or -CH = CH
Represents -C (Y) = CH-CH =. Here, Y represents a quaternized heterocyclic nucleus represented by the general formula (2) (the symbols have the same meanings as described above).
【化２】 シアニン系色素の具体例としては以下のような色素を例
示することができる。[Chemical 2] Specific examples of the cyanine dye include the following dyes.
【化３】 [Chemical 3]
【化４】 [Chemical 4]
【化５】 [Chemical 5]
【化６】 [Chemical 6]
【化７】 [Chemical 7]
【化８】 [Chemical 8]
【化９】 [Chemical 9]
【化１０】 [Chemical 10]
【化１１】 [Chemical 11]
【化１２】 [Chemical 12]
【化１３】 [Chemical 13]
【化１４】 [Chemical 14]
【０００７】[0007]
【作用】癌細胞にシアニン色素を注入し、光照射すると
シアニン色素の光増感作用によって、貧食細胞であるマ
クロファージ（Ｍφ）が活性化し、しかも通常のレベル
以上に活性化してスーパーＭφになることが見出され
た。この現象につきさらに詳しく検討を重ねたところ、
このスーパーＭφが生体の免疫機能を著しく高めること
が分かった。すなわち、光免疫療法とはスーパーＭφが
生体内の異物を排除することを利用して、多くの癌治療
として広く利用できる療法である。抗腫瘍作用の発現メ
カニズムについては、光免疫反応によって活性化マクロ
ファージ、キラーＴ細胞、Ｋ細胞、ＮＫ細胞、線維芽細
胞、マストセル、抗体、補体、サイトカイン、コラーゲ
ンなどによる局所免疫サーキットが腫瘍組織内に極めて
効率よく発現するためと考えられた。例えば、癌患者に
この療法を用いた場合、癌に対する抵抗力は著しく強化
される。生体の免疫反応を過剰に増強し、癌の一部を殺
傷する。破壊された癌細胞に対して生体防御機能の一つ
である創傷治癒機転が増強され、生き残った癌細胞の間
質にコラーゲンを増殖させ、癌を封じ込め瘢痕化すると
いう著しい効果を見出した。動物皮下に移植したヒト癌
で実験を行なったところ、癌は瘢痕化し、押し出されて
脱落することによって、本法の治療効果が確認された。
注入される色素の量は、癌の大きさによって左右される
が、極めて微量で内服、静脈注射など全身的な場合は２
０〜２００μｇを投与すればよく、癌組織内に局所注入
する場合は３〜１００ｎｇ／ｍｌの濃度で十分である。
また、本発明の注入部は体の深部にまで照射可能な装置
であることが大きな特徴である。目的の組織に色素を局
所注入して分散させたあと、光を照射するのであるが、
これら色素は特有の極大吸収波長を有しており、この波
長を含む光線を光源として選び、光照射すると局所にス
ーパーＭφが効率よく出現される。本発明で使用される
光源はレーザー発振器（半導体レーザー、ヘリウム−ネ
オンレーザー、色素レーザー、固体レーザーなど）、ハ
ロゲンランプや発光ダイオードなどが適切である。治療
は可視光または近赤外光を用いて実施することができる
が、一般に生体組織への光線透過性は長波長光ほど良好
であることから、長波長可視光や近赤外光の方が実用上
望ましく、実用に際しては約５００〜８５０ｎｍに極大
吸収波長を有する色素が選択される。また光源の強さ
は、数ルクスから数百ルクスまでの微弱光で十分効果を
発揮する。このときの光線量はＰＤＴに比べて１万分の
１程度と極めて微量である。[Function] When a cyanine dye is injected into cancer cells and irradiated with light, the photosensitizing action of the cyanine dye activates macrophages (Mφ), which are phagocytes, and becomes super Mφ by activating above normal levels. It was found. After further detailed study of this phenomenon,
It was found that this super Mφ significantly enhances the immune function of the living body. That is, the photoimmunotherapy is a therapy that can be widely used as a treatment for many cancers by utilizing the fact that Super Mφ eliminates foreign substances in the living body. Regarding the mechanism of antitumor action, the local immune circuit by activated macrophages, killer T cells, K cells, NK cells, fibroblasts, mast cells, antibodies, complements, cytokines, collagen, etc. is activated in the tumor tissue by photoimmunological reaction. It was considered that the expression was extremely efficient. For example, resistance to cancer is significantly enhanced when using this therapy in cancer patients. It excessively enhances the body's immune response and kills some cancers. We found that the wound healing mechanism, which is one of the body's defense functions, was enhanced against the destroyed cancer cells, that collagen was proliferated in the stroma of the surviving cancer cells, and that the cancer was contained and scarred. When a human cancer transplanted subcutaneously into an animal was tested, the effect of this method was confirmed by the fact that the cancer scarred and was extruded and shed.
The amount of dye injected depends on the size of the cancer, but it is extremely small, and it is 2 in the case of systemic administration such as oral administration and intravenous injection.
It suffices to administer 0 to 200 μg, and a concentration of 3 to 100 ng / ml is sufficient for local injection into cancer tissue.
In addition, the injection part of the present invention is characterized in that it is a device that can irradiate deep parts of the body. The dye is locally injected into the target tissue to disperse it, and then it is irradiated with light.
These dyes have a peculiar maximum absorption wavelength, and when a light ray containing this wavelength is selected as a light source and irradiated with light, super Mφ appears efficiently locally. The light source used in the present invention is preferably a laser oscillator (semiconductor laser, helium-neon laser, dye laser, solid-state laser, etc.), a halogen lamp, a light emitting diode, or the like. Treatment can be carried out using visible light or near-infrared light, but in general, light transmittance to living tissue is better for long-wavelength light, so long-wavelength visible light or near-infrared light is preferable. Practically desirable, a dye having a maximum absorption wavelength of about 500 to 850 nm is selected for practical use. In addition, the intensity of the light source is sufficiently effective at weak light of several lux to several hundred lux. The amount of light rays at this time is about 1 / 10,000 as compared with PDT, which is an extremely small amount.
【０００８】[0008]
【シアニン色素の光免疫作用】マウス腹腔から取り出し
た腹腔滲出細胞をＦＣＳ ｍｅｄｉｕｍ１９９に分散さ
せ１×１０６個／ｍｌに調整する。これにシアニン色素
３ｎｇ／ｍｌを加えて、ハロゲンランプの光を１０ＪＭ
−２照射する。５％ＣＯ２インキュベーターで２時間培
養する。この吸着細胞をＢｉａｎｃｏらの方法でＭφの
貧食能を測定した。その結果、第１表に示すように著し
い貧食能の上昇が認められた。なお表中の数値はＭφ１
００個当たりの貧食した感作赤血球の数を示す。 [Photoimmunity action of cyanine dye] Peritoneal exudate cells taken out from the abdominal cavity of a mouse are dispersed in FCS medium 199 to adjust to 1 × 10 6 cells / ml. Cyanine dye 3 ng / ml was added to this and the light of halogen lamp was adjusted to 10 JM.
-2 irradiate. Incubate for 2 hours in a 5% CO 2 incubator. The phagocytosis of Mφ of the adsorbed cells was measured by the method of Bianco et al. As a result, as shown in Table 1, a marked increase in the dietary deficiency was observed. The values in the table are Mφ1
The number of sensitized red blood cells that have been phagocytosed per 00 is shown.
【０００９】[0009]
【動物実験１】ＨＬＣ（人肺癌）を移植したヌードマウ
スに３日目からルミンを２０ｎｇ静脈注射する。同時に
ハロゲンランプを移植癌に３０分間照射する。週３回繰
り返し、１００日目の癌の瘢痕化の状態を観察した。そ
の結果、第２表に示すように照射時間に関係なく効果が
認められた。 表中の数値は瘢痕化の程度を示したもので１０匹の平均
値を示す。（評価方法：廠痕化の割合，０：０％，１：
２５％以下，２：２５−５０％，３：５０−７５％，
４：７５％以上，５：１００％）。[Animal Experiment 1] From the 3rd day, 20 ng of lumin is intravenously injected to nude mice transplanted with HLC (human lung cancer). At the same time, the transplanted cancer is irradiated with a halogen lamp for 30 minutes. Repeated three times a week, the state of cancer scarring on the 100th day was observed. As a result, as shown in Table 2, the effect was recognized regardless of the irradiation time. The numerical values in the table show the degree of scarring, and the average value of 10 animals is shown. (Evaluation method: rate of scarification, 0: 0%, 1:
25% or less, 2: 25-50%, 3: 50-75%,
4: 75% or more, 5: 100%).
【００１０】[0010]
【動物実験２】ＨＬＣを移植したヌードマウスに３０日
目から本発明による装置を使用して、ルミン５０ｎｇ／
ｍｌを癌組織内に注入する。半導体レーザーで３分間照
射した。この操作を週２回合計４回行った。その結果、
癌組織の瘢痕化が起こり１８０日目には脱落した。[Animal Experiment 2] From the 30th day on nude mice transplanted with HLC, using the device according to the present invention, 50 mg / l of lumin
Inject ml into the cancer tissue. Irradiation with a semiconductor laser was performed for 3 minutes. This operation was performed twice a week for a total of four times. as a result,
Scarring of the cancer tissue occurred, and it fell off on the 180th day.
【００１１】[0011]
【発明の効果】本発明は、シアニン色素の投与と光照射
を組み合わせた、簡単な操作で正確に実施することので
きる光免疫療法による癌治療装置を提供する。本装置は
臨床では超音波画像診断装置と併用され、先端部をモニ
ターしながら生体深部の癌巣に導き、色素注入と光照射
を行ない、局所の免疫反応を誘発する全く新しい癌治療
を行うことのできる装置である。本発明の装置は肝癌、
子宮癌、乳癌、胃癌など注射が行なえる場所にある癌で
あれば使用可能である。とにかくシアニン色素と光の作
用によりＭφを活性化して異物の排除を高めるものであ
るから、その２〜３週間後に、バイオプシーによってＭ
φ、リンパ球の集結、あるいは、これら細胞の出すサイ
トカインを確認することによって容易に、しかも早期に
治療効果の有無の確認が可能である。また、本発明に係
る装置によれば照射した組織でのみ起こる癌細胞障害性
の局所反応であり、目的とする組織で反応のスタートで
あるＭφの活性化を著しく上昇させるので極めて治療効
果がよく、また宿主側から考えた場合、安全性の高いシ
アニン色素を微量使用することや微弱光を照射すること
と併わせ、副作用のない理想的な治療を行うことができ
る。INDUSTRIAL APPLICABILITY The present invention provides a cancer treatment apparatus using photoimmunotherapy which is a combination of administration of a cyanine dye and light irradiation and can be accurately carried out by a simple operation. In clinical use, this device is used in combination with an ultrasonic diagnostic imaging device, and while monitoring the tip, it leads to a cancer nest in the deep part of the living body, performs dye injection and light irradiation, and performs a completely new cancer treatment that induces a local immune reaction. It is a device that can The device of the present invention is for liver cancer,
Any cancer that can be injected such as uterine cancer, breast cancer, gastric cancer can be used. Anyway, it activates Mφ by the action of the cyanine dye and light to enhance the elimination of foreign matter, so 2-3 weeks later, the biopsy causes M
By confirming φ, lymphocyte aggregation, or cytokines produced by these cells, the presence or absence of therapeutic effect can be confirmed easily and early. Further, according to the device of the present invention, it is a local reaction of cancer cytotoxicity that occurs only in the irradiated tissue and the activation of Mφ that is the start of the reaction in the target tissue is remarkably increased. In addition, considering the host side, it is possible to perform an ideal treatment without side effects by using a very safe cyanine dye in a small amount and irradiating with weak light.
【００１２】[0012]
図１は本発明になる光免疫療法による癌治療装置の概略
説明図、図２はかかる装置に用いる注射針の概略説明
図、図３〜図５は留置針の概略説明図である。FIG. 1 is a schematic explanatory view of a cancer treatment device by photoimmunotherapy according to the present invention, FIG. 2 is a schematic explanatory view of an injection needle used in such a device, and FIGS. 3 to 5 are schematic explanatory views of an indwelling needle.
１は光源部、２は光誘導部、３は注入部、４は光導入
路、５は注入部の先端部、６は薬液流入路、７は薬液注
入器、８は薬液注入器と薬液流入路を継ぐコック機能つ
きコネクター、９は光誘導部と光導入路を継ぐコネクタ
ー、１０は留置針の外管、１１は針、１２はゴムシー
ル、１３は針導入口、１４は薬液流入口、１５は光ファ
イバー、１６は光ファイバー導入口、１７はネジを示
す。1 is a light source part, 2 is a light guide part, 3 is an injection part, 4 is a light introduction path, 5 is a tip of the injection part, 6 is a chemical solution inflow path, 7 is a chemical solution injector, 8 is a chemical solution injector and a chemical solution inflow Connector with cock function for connecting the passage, 9 for connecting the light guiding portion and the light introducing passage, 10 for the outer tube of the indwelling needle, 11 for the needle, 12 for the rubber seal, 13 for the needle introducing port, 14 for the chemical liquid inlet, 15 Is an optical fiber, 16 is an optical fiber inlet, and 17 is a screw.
Claims (5)
流入路から構成される注入部を備えた光免疫療法による
癌治療装置。1. A cancer treatment apparatus by photoimmunotherapy, comprising a light source section, a light guide section, and an injection section composed of a light introduction path and a drug solution inflow path.
光ダイオードを使用することを特徴とする請求項１の光
免疫療法による癌治療装置。2. The apparatus for cancer treatment by photoimmunotherapy according to claim 1, wherein a laser oscillator or a light emitting diode is used as a light source unit.
とを特徴とする請求項１の光免疫療法による癌治療装
置。3. The cancer treatment device by photoimmunotherapy according to claim 1, wherein a cyanine dye is used as a liquid medicine.
えた留置針。5. An indwelling needle equipped with an optical fiber introducing port and a drug solution inflow port.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP06124802A JP3082123B2 (en) | 1993-09-30 | 1994-04-26 | Cancer treatment device by photoimmunotherapy |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27883093 | 1993-09-30 | ||
| JP5-278830 | 1993-09-30 | ||
| JP06124802A JP3082123B2 (en) | 1993-09-30 | 1994-04-26 | Cancer treatment device by photoimmunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9207032A Division JPH1071212A (en) | 1997-06-25 | 1997-06-25 | Medical treatment device |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07144026A true JPH07144026A (en) | 1995-06-06 |
| JP3082123B2 JP3082123B2 (en) | 2000-08-28 |
Family
ID=26461399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP06124802A Expired - Fee Related JP3082123B2 (en) | 1993-09-30 | 1994-04-26 | Cancer treatment device by photoimmunotherapy |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3082123B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019130166A (en) * | 2018-02-01 | 2019-08-08 | 株式会社セイバー | Light emission type treatment tool |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002200181A (en) | 2000-10-31 | 2002-07-16 | Shigehiro Kubota | Laser treatment instrument |
| KR101682676B1 (en) * | 2015-05-28 | 2016-12-06 | 주식회사 씨앤지옵틱 | Diffusion Lens having Scaterring Function for LED lighting |
-
1994
- 1994-04-26 JP JP06124802A patent/JP3082123B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019130166A (en) * | 2018-02-01 | 2019-08-08 | 株式会社セイバー | Light emission type treatment tool |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3082123B2 (en) | 2000-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108778413B (en) | Catheter device, kit and composition | |
| Taber et al. | Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study. | |
| Dougherty et al. | Photodynamic therapy | |
| Wilson | Photodynamic therapy for cancer: principles | |
| US5405369A (en) | Photochemical ablation of gastro-intestinal tissue for augmentation of an organ | |
| Kochneva et al. | Photosensitizer Radachlorin®: Skin cancer PDT phase II clinical trials | |
| US20080249517A1 (en) | Light Coupling Adapter Device For Photodynamic Or Photothermal Therapy Or Photodynamic Diagnosis, Corresponding System And Method | |
| Magne et al. | Photodynamic therapy of facial squamous cell carcinoma in cats using a new photosensitizer | |
| Gomer et al. | The effect of localized porphyrin photodynamic therapy on the induction of tumour metastasis | |
| JP2007508860A (en) | Photodynamic therapy to reduce adipocytes locally | |
| CA2339384C (en) | Improved method for targeted topical treatment of disease | |
| KR20140110757A (en) | Use of Photosensitizer In Preparation of Virus-Inactivating Medicaments For Treating Diseases | |
| Protti et al. | Targeting photochemical scalpels or lancets in the photodynamic therapy field—the photochemist's role | |
| Jin et al. | Photodynamic therapy for upper gastrointestinal tumours over the past 10 years | |
| CN103893761A (en) | Ultrasonic-assisted optothermal agent-based tumor cell killing method and system and application thereof | |
| Wilson et al. | Photodynamic therapy | |
| Kujundžić et al. | A Phase II safety and effect on time to tumor progression study of intratumoral light infusion technology using talaporfin sodium in patients with metastatic colorectal cancer | |
| Land | Porphyrin phototherapy of human cancer | |
| JPH07144026A (en) | Cancer treating device by photoimmune treatment method | |
| JPH1071212A (en) | Medical treatment device | |
| Hashimoto et al. | Novel After‐loading Interstitial Photodynamic Therapy of Canine Transmissible Sarcoma with Photofrin II and Excimer Dye Laser | |
| WO2007149951A2 (en) | Systems and methods for use of luminescent compounds in disease treatment and medical imaging | |
| EP2813245B1 (en) | Use of carbamide peroxide injection in preparation of virus inactivation medicaments in combination with photodynamic therapy | |
| RU2098092C1 (en) | Composition for contrasting internal structure of biological objects in laser tomography | |
| Bartoli | Photodynamic Therapy in Skin Treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070630 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080630 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090630 Year of fee payment: 9 |
|
| LAPS | Cancellation because of no payment of annual fees |